Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Manton Center for Orphan Disease Research, Howard Hughes Medical Institute, Children's Hospital Boston and Dana Farber Cancer Institute; Division of Hematology, Brigham and Women's Hospital; and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute, Cambridge, MA 02142, USA; Harvard Stem Cell Institute; Boston, MA 02138, USA.
Cell Stem Cell. 2012 Jun 14;10(6):740-749. doi: 10.1016/j.stem.2012.05.010.
Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies. However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely practiced outside the standard clinical trial network, threatening the cause of legitimate clinical investigation. Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve meaningful clinical impact.
干细胞是组织修复和再生的种子,也是新型疗法的有前途的来源。然而,除了造血干细胞(HSC)移植之外,基本上所有其他干细胞治疗仍然处于实验阶段。高期望激发了无数临床试验,但很难获得明确的证据证明其具有强大的临床益处。近年来,未经证实的疗法在标准临床试验网络之外得到了广泛应用,威胁到合法临床研究的开展。在新型干细胞疗法能够产生有意义的临床影响之前,必须克服众多挑战和技术障碍。